2023
DOI: 10.1038/s41598-023-32515-6
|View full text |Cite
|
Sign up to set email alerts
|

A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress

Abstract: Although beta-amyloid (Aβ) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer’s disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation and oxidative stress. In mild cognitive impairment (MCI), a prodromal stage of AD and other neurodegenerative conditions, the joint appearance of inflammation, oxidative stress, and metabolic alterations are the common pathways of neurotoxicity and neurodegenerati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 15 publications
(6 citation statements)
references
References 63 publications
0
6
0
Order By: Relevance
“…It also displays pharmacological activities such as antimicrobial and anti‐inflammatory capacities (Panasiak et al, 1989 ), although sometimes showing counteractive activity against certain other flavonoids which exert pro‐oxidant activities by catalyzing oxygen radical generation (Hodnick et al, 1986 ). To date, rutin has been considered as a nontoxic chemical, which may be useful in numerous biomedical applications, while some rutin‐containing natural plant extracts such as Ginkgo biloba extract (GBE) demonstrated vital health benefits such as those observed in alleviation of chronic neurodegenerative diseases and reduction in extracellular amyloid beta (Aβ) plaques, typical symptoms of Alzheimer's disease (AD) (Morato et al, 2023 ). By contrast, the potential of rutin in other situation, particularly those involving antiaging properties in advanced stage and the potential of using its bioactivity in development of senotherapeutics, more specifically senomorphics, remains largely underexplored.…”
Section: Introductionmentioning
confidence: 99%
“…It also displays pharmacological activities such as antimicrobial and anti‐inflammatory capacities (Panasiak et al, 1989 ), although sometimes showing counteractive activity against certain other flavonoids which exert pro‐oxidant activities by catalyzing oxygen radical generation (Hodnick et al, 1986 ). To date, rutin has been considered as a nontoxic chemical, which may be useful in numerous biomedical applications, while some rutin‐containing natural plant extracts such as Ginkgo biloba extract (GBE) demonstrated vital health benefits such as those observed in alleviation of chronic neurodegenerative diseases and reduction in extracellular amyloid beta (Aβ) plaques, typical symptoms of Alzheimer's disease (AD) (Morato et al, 2023 ). By contrast, the potential of rutin in other situation, particularly those involving antiaging properties in advanced stage and the potential of using its bioactivity in development of senotherapeutics, more specifically senomorphics, remains largely underexplored.…”
Section: Introductionmentioning
confidence: 99%
“…Morató et al. ( 367 ) investigated the effects of EGb 761, the standardized extract of Ginkgo biloba , in MCI patients. Blood markers of inflammation and oxidative stress were analyzed.…”
Section: Contemporary Approaches In Clinical Trials For Managing Neur...mentioning
confidence: 99%
“…EGb 761 ® , an extract made from the dry leaves of Ginkgo biloba, was found to have strong free radical scavenging and mitochondrial-protective properties [ 174 ], mechanisms that seem to underlie the described protective effects, such as improved neuronal function [ 175 ] and neuroinflammation [ 176 ], a shift in APP metabolism towards non-amyloidogenic pathways [ 177 ], Aβ toxicity, and cognitive performance [ 178 ]. In this context, presently, the antioxidant and anti-inflammatory effects of EGb 761 ® are being evaluated in a Phase IV randomized, open-label clinical trial in MCI subjects to identify its possible clinical correlation with cognitive outcomes (NCT05594355) [ 179 ]. Complementing the existing data on to the neuroprotective effects of EGb 761 ® , recent studies have also investigated the effects of one of its main active components, Ginkgolide B, in the AD context.…”
Section: Mitochondria-based Therapies For Alzheimer’s Diseasementioning
confidence: 99%